longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Tiziana Life Sciences

TLSA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Editas Medicine -16.41%, consensus target above spot

    Weekly Review·2 days ago, 08:10 AM
    EDIT+2.41%
  • Weekly Recap | Caris Life Sciences -2.91%, most brokers rate it buy

    Weekly Review·2 days ago, 07:49 AM
    CAI+4.03%
  • Weekly Recap | Abbvie +0.26%, most brokers rate it buy

    Weekly Review·2 days ago, 07:40 AM
    ABBV+1.69%
  • Weekly Recap | Twist Bioscience +2%, consensus target below spot

    Weekly Review·2 days ago, 07:00 AM
    TWST+6.10%
  • Weekly Recap | Sellas Life Sciences -16.7%, Friday's heavy-volume slide

    Weekly Review·2 days ago, 06:47 AM
    SLS+3.07%
  • Weekly Recap | Revolution Medicines -2.98%, consensus target above spot

    Weekly Review·2 days ago, 06:40 AM
    RVMD+0.62%
  • Weekly Recap | Regeneron Pharma -5.59%, class action deadline passes

    Weekly Review·2 days ago, 06:39 AM
    REGN+1.94%
  • Weekly Recap | Natera +0.23%, consensus target above spot

    Weekly Review·2 days ago, 06:29 AM
    NTRA+2.34%
  • Weekly Recap | Larimar Therapeutics +2.35%, most brokers rate it buy

    Weekly Review·2 days ago, 06:12 AM
    LRMR-0.89%
  • Weekly Recap | Incyte -4.17%, consensus rating still buy

    Weekly Review·2 days ago, 06:05 AM
    INCY+0.86%
  • Weekly Recap | SPDR S&P Biotech -4.65%, most brokers rate it buy

    Weekly Review·2 days ago, 05:07 AM
    XBI+1.24%LABD-3.54%